Careful selection of building block properties and compatibility essential to boost the overall success of multispecifics
03 Nov 2026
Formats & Scaffolds
- When you screen building blocks individually, what predicts (or fails to predict) how they'll behave once combined?
- How do you decide format before knowing your final pairing — or does format selection happen iteratively?
- What's a compatibility failure mode you didn't see coming until late-stage development?
- Is there a "universal" scaffold, or is format selection always going to be target/biology-specific?
- How much should manufacturability constraints shape building-block choice upstream, versus optimizing for potency first and fixing developability later?
- How much effort should be invested in characterizing individual building blocks when many developability liabilities only emerge in the final molecule? Which assays are most informative upstream, and which are only meaningful on the final format?
- For smaller scaffolds, understanding PK and biodistribution often become key challenges. How do you assess and de-risk these properties early in discovery? What assays, models, or computational approaches have proven most predictive, and what lessons have you learned along the way?
- Looking back over the past ~5 years, what was a commonly held assumption about formats, scaffolds, or developability that later proved incorrect? How did that change your team's decision-making process?
Industry Expert
